Across TCGA pan-cancer cohorts, ST3GAL2 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ST3GAL2 data layer compared with 27 for mass-spec protein and 7 for mutation status.
The strongest signal is observed in glioblastoma multiforme (GBM), where higher ST3GAL2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ST3GAL2 expression acts as an unfavorable survival marker.
GBM are the cancer types where ST3GAL2 mass-spec protein most reproducibly stratifies survival.